Magenta Therapeutics has reported that Phase II clinical trial of MGTA-145 in combination with plerixafor in multiple myeloma patients met the primary endpoint.

All ten subjects met the primary goal of mobilising two million CD34+ stem cells per kg in up to two days of same-day mobilisation and apheresis, preliminary results showed.

The investigator-initiated, Phase II open-label trial is evaluating whether MGTA-145 plus plerixafor can gather stem cells for autologous stem cell transplant in the trial subjects.

Progressing currently at the Stanford University School of Medicine, US, the trial will enrol a total of 25 participants.

The preliminary data from the trial also showed that nine out of ten subjects met the primary endpoint in a day.

In a day, the median number of stem cells accumulated was 5.4 million CD34+ stem cells per kg.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

All six transplanted subjects were found to be effectively engrafted and the median recovery of neutrophils after 12 days and platelets after 17 days were seen to be within anticipated levels in multiple myeloma.

In addition, the MGTA-145 plus plerixafor treatment was found to be well tolerated in the trial.

Magenta Therapeutics president and CEO Jason Gardner said: “A patient’s ability to mobilise is highly contingent on a variety of risk factors, which is particularly relevant for blood cancer patients.

“These initial results provide insight into MGTA-145 plus plerixafor’s ability to improve the approach to mobilisation and collection, and its potential to be a first-line mobilisation drug in this and other disease areas.”

Furthermore, the company is set to submit an Investigational New Drug (IND) application for its MGTA-117 drug candidate next month.

Magenta expects to commence the Phase I/II clinical trial of MGTA-117 for treating patients with relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes soon.

This dose-escalation trial will assess the safety, pharmacokinetic and pharmacodynamic profile of MGTA-117 as monotherapy.